デフォルト表紙
市場調査レポート
商品コード
1231654

子宮内膜症治療薬の世界市場

Endometriosis Drugs

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 191 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
子宮内膜症治療薬の世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 191 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

子宮内膜症治療薬の世界市場は2030年に33億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に27億米ドルと推定される子宮内膜症治療薬の世界市場は、2030年までに33億米ドルの改定規模に達し、2022年から2030年にかけてCAGR2.6%の成長を遂げると予測されます。本レポートで分析したセグメントの一つであるホルモン療法は、CAGR3%を記録し、分析期間終了時には20億米ドルに達すると予測されます。パンデミック後の回復が進んでいることを考慮し、鎮痛剤分野の成長は、今後8年間のCAGRが2%に修正されます。

米国市場は7億7,780万米ドル、中国はCAGR2.4%で成長すると予測

米国の子宮内膜症治療薬市場は、2022年に77,780万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが2.4%となり、2030年には5億8,010万米ドルの市場規模に達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ2.3%と2%の成長が予測されています。欧州では、ドイツがCAGR2.4%で成長すると予測されています。

調査対象企業の例

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Debiopharm Group
  • Evotec AG
  • Kissei Pharmaceutical Co. Ltd.
  • Neurocrine Biosciences Inc.
  • ObsEva SA
  • Pfizer Inc.
  • Repros Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • ValiRx plc

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-6433

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Endometriosis Drugs Market to Reach $3.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Endometriosis Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$3.3 Billion by 2030, growing at aCAGR of 2.6% over the period 2022-2030. Hormone therapy, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Analgesics segment is readjusted to a revised 2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $777.8 Million, While China is Forecast to Grow at 2.4% CAGR

The Endometriosis Drugs market in the U.S. is estimated at US$777.8 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$580.1 Million by the year 2030 trailing a CAGR of 2.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Select Competitors (Total 38 Featured):

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Debiopharm Group
  • Evotec AG
  • Kissei Pharmaceutical Co. Ltd.
  • Neurocrine Biosciences Inc.
  • ObsEva SA
  • Pfizer Inc.
  • Repros Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • ValiRx plc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Endometriosis: An Introductory Prelude
    • Recent Market Activity
    • Endometriosis Facts in a Nutshell
    • Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
    • Key Endometriosis Drugs on the Market
    • The Pipeline Review
    • Key Endometriosis Drugs in the Pipeline: 2017
    • Endometriosis Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • AbbVie Inc. (USA)
    • Astellas Pharma Inc. (Japan)
    • AstraZeneca Plc (UK)
    • Bayer AG (Germany)
    • Debiopharm Group (Switzerland)
    • Evotec AG (Germany)
    • Kissei Pharmaceutical Co., Ltd. (Japan)
    • Neurocrine Biosciences, Inc. (USA)
    • ObsEva SA (Switzerland)
    • Pfizer, Inc. (USA)
    • Repros Therapeutics, Inc. (USA)
    • Roivant Sciences GmbH (Switzerland)
    • Takeda Pharmaceutical Company Limited (Japan)
    • ValiRx plc (UK)
  • 3. MARKET TRENDS & DRIVERS
    • Steady Growth Expected Over the Next Few Years
    • Emerging Treatment for Endometriosis & Endometrial Cancer
    • Global Awareness Campaigns and Efforts
    • Uptrend in Healthcare Expenditure Creates Substantial Opportunities
    • Developed Regions Remain Primary Revenue Contributors
    • Developing Regions Exhibit Immense Growth Potential
    • Stable Economic Scenario to Augment Market Prospects
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Endometriosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • JAPAN
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • CHINA
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: China 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • EUROPE
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • FRANCE
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: France 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • GERMANY
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Rest of Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Rest of Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Asia-Pacific 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Rest of World Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Rest of World 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030

IV. COMPETITION